Fact Check: Does Zepbound Really Outperform Wegovy by 47%?

SURMOUNT-5 showed tirzepatide produced 47% more weight loss than semaglutide. Here's what the trial actually found, what the number means, and what's missing from the headline.

In late 2024, Eli Lilly released results from SURMOUNT-5, a head-to-head clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) for weight management. The trial's top-line finding — that tirzepatide produced approximately 47% greater weight loss than semaglutide — generated significant press coverage and has been used extensively in marketing claims for tirzepatide ever since.

The 47% figure is real, but it requires context to be interpreted correctly. This source check unpacks what SURMOUNT-5 actually measured, what the comparative result means clinically, and how it should inform patient decisions.

Trial Design

SURMOUNT-5 was a 72-week, randomized, open-label, multicenter trial comparing tirzepatide to semaglutide at their respective highest approved weight-management doses in adults with obesity (or overweight plus weight-related comorbidity) without type 2 diabetes. The trial was powered for superiority on percent body weight change from baseline as the primary endpoint. Participants were randomized to tirzepatide titrated to the maximum tolerated dose (up to 15 mg weekly) or semaglutide titrated to 2.4 mg weekly.

The primary analysis reported percent body weight change at week 72. Secondary endpoints included proportion of participants achieving ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% weight loss; changes in cardiometabolic parameters; and safety endpoints.

What 47% Actually Means

The 47% figure is calculated as the relative difference between mean percent weight loss in the two arms. Tirzepatide achieved about 20.2% mean body weight reduction; semaglutide achieved about 13.7%. The ratio of those — (20.2 - 13.7) / 13.7, or roughly 47% — is where the headline comes from.

In absolute terms, the difference is 6.5 percentage points of body weight. For a 200-pound patient, that's about 13 pounds of additional weight loss on tirzepatide versus semaglutide. That is clinically meaningful, but it's a different framing than "47% more effective," which can be heard as "half again as much" on an absolute scale.

Important Context Missing From the Headline

First, the comparison was at maximum doses in both arms. Not all patients tolerate maximum doses — gastrointestinal side effects can limit tolerability, and real-world dosing is often lower than protocol dosing. The advantage of tirzepatide over semaglutide is likely smaller at equivalent real-world doses.

Second, the trial was open-label, not blinded. Open-label design can introduce expectation bias in weight-management trials, where adherence to lifestyle interventions may be influenced by knowledge of treatment assignment. Whether this materially affected the result is debatable, but it's a methodological note worth mentioning.

Third, SURMOUNT-5 measured weight loss. It did not measure long-term outcomes like cardiovascular events, kidney disease progression, or mortality. For those outcomes, the comparative data is less complete — semaglutide has the SELECT and FLOW trials establishing cardiovascular and kidney benefits; tirzepatide has SURPASS-CVOT and related programs, but the evidence bases are not identical in depth or duration.

The Individual Patient Question

SURMOUNT-5 doesn't answer which drug an individual patient should choose. It establishes that tirzepatide is, on average, more effective for weight loss than semaglutide at top doses over 72 weeks. But individual response varies widely, side-effect profiles differ, insurance coverage varies, and real-world dosing is often below maximum.

For patients starting therapy, the practical decision often comes down to which drug is accessible (coverage, availability), tolerable (side-effect profile), and affordable (cash-pay price or copay). Both drugs produce clinically meaningful weight loss; the choice between them is not a simple one-size-fits-all. For more, see our STEP program review and SURPASS-CVOT review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.